Paying for Mental Health Care

What 'Failing Two Antidepressants' Actually Means for TMS Coverage

Save

To insurers, a 'failed' antidepressant is one tried at an adequate dose for an adequate duration that either did not work well enough or could not be tolerated. Many plans want two or more documented trials before approving TMS, though what counts as adequate varies by payer.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What does 'failing an antidepressant' mean to an insurer?

To a plan, a failed trial is a specific, documentable event, not a feeling of discouragement. It generally means a medication was taken at a therapeutic dose for a sustained period, typically several weeks. It then either did not reduce your depression enough or produced side effects you could not tolerate 2. Both outcomes, inadequate response and intolerance, usually count as a failed trial. The key is that the attempt was a genuine, adequately dosed course rather than a few days that were stopped early. Because plans rely on your chart to verify this, the record your prescriber keeps is what ultimately establishes that a trial occurred.

Why do plans require two failed trials for TMS?

Insurers use step-therapy logic: they generally ask that lower-cost, first-line treatments be tried before approving a more resource-intensive one 3. TMS is typically framed as a treatment for treatment-resistant depression, meaning depression that has not responded to standard medication 1. Health-technology analyses evaluate TMS specifically in that treatment-resistant population, which is part of why payers set a documented-failure threshold before authorizing it 1. The exact number of required trials is a plan-level policy decision, so while two is common, some plans ask for more and some, including certain Medicare policies, may accept fewer.

How do payers define an 'adequate trial'?

Adequacy has two parts: dose and duration. A plan usually wants evidence that the medication reached a recognized therapeutic dose and was continued long enough for a fair assessment, rather than stopped in the first days 2. Because antidepressants differ in how and when they work, plans may also want the two trials to involve different medications or drug classes; research comparing many antidepressants underscores that response varies from one drug to another 4. The precise dose and week thresholds that count as adequate are set in each plan's written medical policy. So the definition can shift between insurers even for the same person.

Where do Medicare and commercial plans differ?

The criteria are not uniform. Commercial plans commonly require two or more adequately dosed antidepressant trials plus documentation of the diagnosis, while some policies also expect a course of psychotherapy. Medicare and Medicare Advantage set their own coverage rules, and certain Medicare policies have applied somewhat different thresholds than commercial plans. Rather than assume, it helps to read your specific plan's medical policy for TMS, which spells out the exact trial count and documentation it wants. If you are on Medicare, our overview of how Medicare covers TMS walks through those rules and the cost that comes with them.

When your prescriber's documentation matters most

Because coverage turns on what is written in your chart, the medication history your prescriber records is doing quiet but decisive work. A clear list of the antidepressants you have tried, the doses, how long you stayed on each, and why each was stopped is what a reviewer looks for. If you gather that history, the prior-authorization request tends to go more smoothly, and if a plan says the criteria are not met, that same record anchors an appeal. Gale can help you assemble a treatment-history summary so nothing that supports your case gets left out.

Common questions

No. To insurers, a failed trial simply means an adequately dosed medication either did not relieve your depression enough or could not be tolerated. It is a clinical and documentation term, not a judgment about effort.

Many commercial plans require two or more adequately dosed trials, though some ask for more and certain Medicare policies may accept fewer. The exact number is set in each plan's written medical policy for TMS.

Generally, the medication must have reached a recognized therapeutic dose and been continued long enough for a fair assessment, usually several weeks. Plans may also want the trials to involve different medications, and the specific thresholds live in each plan's policy.

Usually yes. Intolerable side effects that led you to stop an adequately dosed medication typically count as a failed trial, alongside trials where the medication simply did not work well enough. Your chart should document the reason it was stopped.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

A note on coverage criteria

  • —If your depression worsens or you have thoughts of self-harm, you can call or text the 988 Suicide and Crisis Lifeline for free, confidential support any time.

This article offers general information about paying for and accessing TMS care; it is not medical advice, a diagnosis, or a guarantee of coverage. Your plan's medical policy and your clinician's judgment govern your situation. If your depression feels worse or you have thoughts of harming yourself, you can reach the 988 Suicide and Crisis Lifeline by calling or texting 988.

References

  1. 1.Health Quality Ontario (2016). Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis. Ontario Health Technology Assessment Series. PMID 27110317 ✓A health-technology economic analysis evaluating repetitive TMS as a treatment delivered as a course for treatment-resistant depression, the population for which payers most often assess and authorize it.
  2. 2.MedlinePlus, U.S. National Library of Medicine (2024). Antidepressants. MedlinePlus, U.S. National Library of Medicine. link ✓Consumer-health reference on antidepressant medications, including that a medication is typically tried at a therapeutic dose for a period of weeks before its response can be judged.
  3. 3.American Medical Association (2025). Prior authorization research & reports. American Medical Association (AMA). link ✓AMA research documenting how prior authorization and step-therapy requirements work in practice, including the documentation plans request and the review timelines patients and clinicians encounter.
  4. 4.Cipriani A, Furukawa TA, Salanti G, et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. doi:10.1016/S0140-6736(17)32802-7 ✓A systematic review and network meta-analysis comparing the efficacy and acceptability of antidepressant drugs for acute treatment of major depressive disorder, underscoring that response varies across medications.

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library